Pfiz­er bags a Langer plat­form, buys Bind as­sets with a $40M bid

In the end, Pfiz­er saw the most val­ue in Bind Ther­a­peu­tics’ plat­form tech­nol­o­gy. Al­ready part­nered on new prod­ucts, Pfiz­er has come up with a win­ning …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.